Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7

Williams, J.Andrew, Ring, Barbara J., Cantrell, Varon E., Jones, David R., Eckstein, James, Ruterbories, Kenneth, Hamman, Mitchell A., Hall, Stephen D. +1 more·2002·Drug Metabolism and Disposition
DOI 10.1124/dmd.30.8.883

Cited by (472)

Items 101–200 of 472

  1. DIFFERENCES IN THE INHIBITION OF CYTOCHROMES P450 3A4 AND 3A5 BY METABOLITE-INHIBITOR COMPLEX-FORMING DRUGS
    Donavon J. McConn, Yvonne S. Lin, Kyle E. Allen, Kent L. Kunze, Kenneth E. Thummel · 2004 · Drug Metabolism and Disposition
  2. Chronic hepatitis C: This and the new era of treatment
    Gaetano Bertino · 2016 · World Journal of Hepatology
  3. DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL
    Ying-Hong Wang, David R. Jones, Stephen David Hall · 2005 · Drug Metabolism and Disposition
  4. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate
    Thomas M. Polasek, John O. Miners · 2006 · European Journal of Clinical Pharmacology
  5. Cell-based models to study hepatic drug metabolism and enzyme induction in humans
    Marc Vermeir, Pieter Annaert, Rao N. V. S. Mamidi, Dirk Roymans, W. Meuldermans, Geert Mannens · 2005 · Expert Opinion on Drug Metabolism & Toxicology
  6. Dynamic Patterns of Histone Methylation Are Associated with Ontogenic Expression of the Cyp3a Genes during Mouse Liver Maturation
    Ye Li, Yue Cui, Steven N. Hart, Curtis D. Klaassen, Xiao Zhong · 2009 · Molecular Pharmacology
  7. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children
    Wangda Zhou, Trevor N. Johnson, Khanh Bui, S.Y. Amy Cheung, Jianguo Li, Hongmei Xu, Nidal H. Al-Huniti, Diansong Zhou · 2017 · Clinical Pharmacology & Therapeutics
  8. Population Pharmacokinetics of Midazolam and Its Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates
    Maurice J. Ahsman, Manon N. Hanekamp, Enno Diederik Wildschut, Dick Tibboel, Ron A. A. Mathôt · 2010 · Clinical Pharmacokinetics
  9. COMPARISON OF METHODS FOR THE PREDICTION OF THE METABOLIC SITES FOR CYP3A4-MEDIATED METABOLIC REACTIONS
    Diansong Zhou, Lovisa Afzelius, Scott W. Grimm, Tommy B. Andersson, Randy J. Zauhar, Ismael Zamora · 2006 · Drug Metabolism and Disposition
  10. CYP3A5 phenotype‐genotype correlations in a British population
    Barry P. King, Julian B. S. Leathart, Elaine Mutch, Faith M. Williams, Ann K. Daly · 2003 · British Journal of Clinical Pharmacology
  11. A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications
    Guang‐Bo Ge, Jing Ning, Lianghai Hu, Ziru Dai, Jie Hou, Yun‐Feng Cao, Zhenwen Yu, Chun‐Zhi Ai, Jingkai Gu, Xiaochi Ma et al. · 2013 · Chemical Communications
  12. DNA methylation dynamics in the hepatic CYP3A4 gene promoter
    Marina Kacevska, Maxim Ivanov, Annika Wyss, Silva Kasela, Lili A. Milani, Anders Rane, Magnus Ingelman‐Sundberg · 2012 · Biochimie
  13. UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES
    Aleksandra Galetin, Caroline Brown, David Hallifax, Kiyomi Ito, James Brian. Houston · 2004 · Drug Metabolism and Disposition
  14. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology
    Jeffrey C. Stevens · 2006 · Drug Discovery Today
  15. Recombinant CYP3A4*17 Is Defective in Metabolizing the Hypertensive Drug Nifedipine, and the CYP3A4*17 Allele May Occur on the Same Chromosome as CYP3A5*3, Representing a New Putative Defective CYP3A Haplotype
    Su‐Jun Lee, Douglas A. Bell, Sherry J. Coulter, Burhan I. Ghanayem, Joyce A. Goldstein · 2005 · Journal of Pharmacology and Experimental Therapeutics
  16. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43
    Solveigh Krusekopf, Ivar Roots, U. Kleeberg · 2003 · European Journal of Pharmacology
  17. Sex differences in CYP3A activity using intravenous and oral midazolam
    M CHEN, L MA, George L. Drusano, J BERTINOJR, Anne N. Nafziger · 2006 · Clinical Pharmacology & Therapeutics
  18. METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES
    Theresa Mariero Klees, Pamela R. Sheffels, Ola Dale, Evan D. Kharasch · 2004 · Drug Metabolism and Disposition
  19. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
    Abdo S. Haddad, Mellar P. Davis, Ruth L. Lagman · 2006 · Supportive Care in Cancer
  20. Effect of CYP3A53 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects
    Kyoung‐Ah Kim, Pil‐Whan Park, O LEE, Sangchun Choi, B MIN, K SHIN, B CHUN, J SHIN, Ji Young Park · 2006 · Clinical Pharmacology & Therapeutics
  21. PhRMA White Paper on ADME Pharmacogenomics
    J. Andrew Williams, Tommy Andersson, Tommy B. Andersson, Rebecca L. Blanchard, Martin Otto Behm, Nadine Cohen, Timi I. Edeki, Monique A. Franc, Kathleen M. Hillgren, Keith J. Johnson et al. · 2008 · The Journal of Clinical Pharmacology
  22. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas
    Susanne Haas, Christiane Barbara Pierl, Volker Harth, Beate Pesch, Sylvia Rabstein, Thomas Brüning, Yon D. Ko, Ute Hamann, Christina Justenhoven, Hiltrud B. Brauch et al. · 2006 · International Journal of Cancer
  23. The Structural Basis for Homotropic and Heterotropic Cooperativity of Midazolam Metabolism by Human Cytochrome P450 3A4
    Arthur G. Roberts, Jingyu Yang, James R. Halpert, Sidney D. Nelson, Kenneth T. Thummel, William M. Atkins · 2011 · Biochemistry
  24. Comparison of Antifungal Azole Interactions with Adult Cytochrome P450 3A4 versus Neonatal Cytochrome P450 3A7
    Malika P. Godamudunage, Anne M. Grech, Emily E. Scott · 2018 · Drug Metabolism and Disposition
  25. Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5
    Chyung S. Cook, Loren Berry, David H. Kim, Earl G. Burton, Jeremy D. Hribar, Liming Zhang · 2002 · Drug Metabolism and Disposition
  26. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
    April N. Tucker, Katherine A. Tkaczuk, Lynn M. Lewis, Dragana Tomic, C.K. Lim, Jodi Anne Flaws · 2004 · Cancer Letters
  27. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
    Michaela Vossen, Michael Sevestre, Christoph Niederalt, In‐Jin Jang, Stefan Willmann, Andrea N. Edginton · 2007 · Theoretical Biology and Medical Modelling
  28. Pharmacokinetic considerations in pediatric pharmacotherapy
    Sin Yin Lim, Rebecca S. Pettit · 2019 · American Journal of Health-System Pharmacy
  29. Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)
    David R. Jones, Sean Ekins, Lang Li, Stephen David Hall · 2007 · Drug Metabolism and Disposition
  30. Identification and phenotype characterization of two haplotypes causing different enzymatic capacity in fetal livers
    Cristina Rodríguez‐Antona, Mary B. Jande, Anders Rane, Magnus Ingelman‐Sundberg · 2005 · Clinical Pharmacology & Therapeutics
  31. Reviewing Data Integrated for PBPK Model Development to Predict Metabolic Drug-Drug Interactions: Shifting Perspectives and Emerging Trends
    Kenza Abouir, Caroline Flora Samer, Yvonne Sylvia Gloor, Jules Alexandre Desmeules, Youssef Daali · 2021 · Frontiers in Pharmacology
  32. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects
    Ji Young Park, Kyoung‐Ah Kim, P PARK, O LEE, Daehee Kang, J SHON, K LIU, Jae‐Gook Shin · 2006 · Clinical Pharmacology & Therapeutics
  33. Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes
    Junling Yang, Minxia Michelle He, Wei Niu, Steven A. Wrighton, Li Li, Yang Liu, Chuan Li · 2011 · British Journal of Clinical Pharmacology
  34. Nifedipine Pharmacokinetics Are Influenced by CYP3A5 Genotype When Used as a Preterm Labor Tocolytic
    Sara K. Quinney, Jayanti M. Clay, Jamie L. Renbarger, Mary F. Hébert, Shannon M. Clark, Jason G. Umans, Steve N. Caritis, David M. Haas, for the Obstetric-Fetal Pharmacology Research Units Network · 2012 · American Journal of Perinatology
  35. ‘African potato’ (Hypoxis hemerocallidea corm): a plant‐medicine for modern and 21st century diseases of mankind? – a review
    Peter M. O. Owira, John A. O. Ojewole · 2008 · Phytotherapy Research
  36. Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism
    Haixing Li, Jed Noah Lampe · 2019 · Archives of Biochemistry and Biophysics
  37. Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes
    Brian Carr, Ryan Norcross, Yulin Fang, Ping Lu, A. David Rodrigues, Magang Shou, Tom H. Rushmore, Catherine L. Booth-Genthe · 2006 · Drug Metabolism and Disposition
  38. Cytochrome P450 3A Polymorphisms and Immunosuppressive Drugs
    Éric Thervet, Christophe M. Legendre, Philippe H. Beaune, Dany Anglicheau · 2005 · Pharmacogenomics
  39. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration
    X REN, Xinliang Mao, Luqin Si, Lei Cao, H XIONG, Jiewen Qiu, Aaron David Schimmer, George Qian Li · 2008 · European Journal of Pharmaceutics and Biopharmaceutics
  40. Development of a Physiologically‐Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content
    Chie Emoto, Tsuyoshi Fukuda, Shareen Cox, Uwe Christians, Alexander A. T. M. M. Vinks · 2013 · CPT Pharmacometrics & Systems Pharmacology
  41. An integrated pharmacokinetics ontology and corpus for text mining
    Heng‐Yi Wu, Shreyas Karnik, Abhinita Subhadarshini, Zhiping Paul Wang, Santosh Philips, Xu Han, Chien‐Wei Chiang, Lei Liu, Malaz A. Boustani, Luis Mateus Rocha et al. · 2013 · BMC Bioinformatics
  42. Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
    Helen E. Cubitt, Karen Rowland Yeo, Eleanor M. Howgate, Amin Rostami‐Hodjegan, Zoe E. Barter · 2011 · Xenobiotica
  43. The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil
    Hei-Young Ku, Hee-Jeong Ahn, Kyung‐Ah Seo, Hyun-Mi Kim, Minkyung Oh, Soo Kyung Bae, Jae‐Gook Shin, Ji‐Hong Shon, Kwang‐Hyeon Liu · 2008 · Drug Metabolism and Disposition
  44. BIOTRANSFORMATION OF FLUTICASONE: IN VITRO CHARACTERIZATION
    Robin E. Pearce, James Steven Leeder, Gregory L. Kearns · 2006 · Drug Metabolism and Disposition
  45. Everolimus dosing recommendations for tuberous sclerosis complex– associated refractory seizures
    David Neal Franz, John A. Lawson, Zühal Yapıcı, Christian Brandt, Michael H. Kohrman, Michael Wong, Mathieu Milh, Adelheid Wiemer‐Kruel, Maurizio Voi, Neva Coello et al. · 2018 · Epilepsia
  46. CYP3A5 Contributes Significantly to CYP3A-mediated Drug Oxidations in Liver Microsomes from Japanese Subjects
    Satoshi Yamaori, Hiroshi Yamazaki, Shunsuke Iwano, Kazuma Kiyotani, Keiko Matsumura, Goro Honda, Kazuko Nakagawa, Takashi Ishizaki, Tetsuya Kamataki · 2004 · Drug Metabolism and Pharmacokinetics
  47. Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7
    Sylvie E. Kandel, Lyrialle W. Han, Qingcheng Mao, Jed Noah Lampe · 2017 · Drug Metabolism and Disposition
  48. Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
    Tomoko Ozeki, Mitsuji Nagahama, Kazuma Fujita, Akifumi Suzuki, Kiminori Sugino, Koichi Ito, Masatomo Miura · 2019 · Scientific Reports
  49. In vitro evaluation of human cytochrome P450 and P-glycoprotein-mediated metabolism of some phytochemicals in extracts and formulations of African potato
    Vipin D. P. Nair, Brian C. Foster, John Thor Arnason, Edward J. Mills, Isadore Kanfer · 2007 · Phytomedicine
  50. Comprehensive Computational Assessment of ADME Properties Using Mapping Techniques
    Konstantin V. Balakin, Yan A. Ivanenkov, Nikolay Savchuk, Andrey A. Ivashchenko, Sean Ekins · 2005 · Current Drug Discovery Technologies
  51. Functional and Morphological Comparison of Three Primary Liver Cell Types Cultured in the AMC Bioartificial Liver
    Poyck, Paul P.C., Hoekstra, Ruurdtje, van Wijk, Albert C.W.A., Attanasio, Chiara, Calise, Fulvio, Chamuleau, Robert A.F.M., van Gulik, Thomas M. · 2007 · Liver Transplantation
  52. Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?
    Elaine Mutch, Ann K. Daly, Julian B. S. Leathart, Peter G. Blain, Faith M. Williams · 2003 · Archives of Toxicology
  53. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers
    Tsuyoshi Fukuda, S Onishi, Shuichi Fukuen, Yuka Ikenaga, Masako Ohno, K Hoshino, Katsumi Matsumoto, A Maihara, Kouichi Momiyama, T Ito et al. · 2003 · The Pharmacogenomics Journal
  54. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5
    Mei‐Hui Hsu, Üzen Savas, Eric F. Johnson · 2017 · Molecular Pharmacology
  55. Assessment of Pharmacokinetic Drug–Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited
    Uwe Fuhr, Chih‐hsuan Hsin, Xia Li, Wafaâ Jabrane, F. Sörgel · 2018 · The Annual Review of Pharmacology and Toxicology
  56. Anterior pituitary, sex hormones, and keratoconus: Beyond traditional targets
    Dimitrios Karamichos, Paulina Escandon, Brenda Vasini, Sarah E. Nicholas, Lyly Van, Deanna H. Dang, Rebecca Lynn Cunningham, Kamran M. Riaz · 2021 · Progress in Retinal and Eye Research
  57. Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer
    Jolantha Beyerle, Eva Frei, Marie Stiborová, Nina Habermann, Cornelia M. Ulrich · 2015 · Drug Metabolism Reviews
  58. In vitro inhibitory effect of West African medicinal and food plants on human cytochrome P450 3A subfamily
    Amégnona Agbonon, Kwashie Eklu‐Gadegbeku, Kodjo A. Aklikokou, Messanvi Gbéassor, Koffi Akpagana, Teresa W. Tam, John Thor Arnason, Brian C. Foster · 2010 · Journal of Ethnopharmacology
  59. Genetic contribution to variable human CYP3A-mediated metabolism
    Jatinder Kaur Lamba, Yvonne S. Lin, Erin G. Schuetz, Kenneth E. Thummel · 2012 · Advanced Drug Delivery Reviews
  60. Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam
    Jingyu Yang, William M. Atkins, Nina Isoherranen, Mary F. Paine, Kenneth E. Thummel · 2011 · Clinical Pharmacology & Therapeutics
  61. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects
    Kyoung‐Ah Kim, Pil-Whan Park, Ji Young Park · 2008 · European Journal of Clinical Pharmacology
  62. Substrate Dependent Inhibition Profiles of Fourteen Drugs on CYP3A4 Activity Measured by A High Throughput LCMS/MS Method with Four Probe Drugs, Midazolam, Testosterone, Nifedipine and Terfenadine
    Jagdish K. Racha, Zhen Zhao, Nicholas Olejnik, Nadine Warner, Rebecca Chan, David Moore, Hiroko Satoh · 2003 · Drug Metabolism and Pharmacokinetics
  63. Microsomal prediction ofin vivoclearance and associated interindividual variability of six benzodiazepines in humans
    Helen C. Rawden, David John Carlile, Andrew J. Tindall, David Hallifax, Aleksandra Galetin, Kiyomi Ito, James Brian. Houston · 2005 · Xenobiotica
  64. Recent advances in the ontogeny of drug disposition
    Brian D. Chapron, Alenka Chapron, James Steven Leeder · 2021 · British Journal of Clinical Pharmacology
  65. Classification of drugs for evaluating drug interaction in drug development and clinical management
    Kazuya Maeda, Akihiro Hisaka, Kiyomi Ito, Yoshiyuki Ohno, Akihiro Ishiguro, Reiko Sato, Naomi Nagai · 2021 · Drug Metabolism and Pharmacokinetics
  66. CYP3A5 polymorphism, amlodipine and hypertension
    Y-P Zhang, X-C Zuo, Z-J Huang, J-J Cai, J Wen, Dayue Darrel Duan, Hong Yuan · 2013 · Journal of Human Hypertension
  67. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients
    Masatomo Miura, Shigeru Satoh, Kazuyuki Inoue, Hideaki Kagaya, Mitsuru Saito, Takamitsu Inoue, Tomonori Habuchi, Toshio Suzuki · 2008 · Steroids
  68. Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: A case study using the BCS/BDDCS Class II drug nifedipine
    Nikunjkumar K. Patel, Sebastian Polak, Masoud Jamei, Amin Rostami‐Hodjegan, David B. Turner · 2013 · European Journal of Pharmaceutical Sciences
  69. Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women
    Ritah Francis Mutagonda, Appolinary A. R. Kamuhabwa, Omary Minzi, Siriel Nanzia Massawe, Muhammad Asghar, Manijeh Vafa Homann, Anna Färnert, Eleni Aklillu · 2017 · Malaria Journal
  70. Active-site differences between substrate-free and ritonavir-bound cytochrome P450 (CYP) 3A5 reveal plasticity differences between CYP3A5 and CYP3A4
    Mei‐Hui Hsu, Eric F. Johnson · 2019 · Journal of Biological Chemistry
  71. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas
    Cristina Rodríguez‐Antona, Susanna Leskelä, Magdalena Zajac, Marta Cuadros, Javier Alvés, Maria Victoria Moneo, Carmen Martín, Juan C. Cigudosa, Amancio Carnero, Mercedes Robledo et al. · 2007 · Blood
  72. Pharmacogenomics of anticoagulants: steps toward personal dosage
    Ann K. Daly · 2009 · Genome Medicine
  73. CYP3A4 and CYP3A7-Mediated Carbamazepine 10,11-Epoxidation Are Activated by Differential Endogenous Steroids
    Hiroyoshi Nakamura, Nao Torimoto, Itsuko Ishii, Noritaka Ariyoshi, Hiromitsu Nakasa, Shigeru Ohmori, Mitsukazu Kitada · 2003 · Drug Metabolism and Disposition
  74. Foetal and adult human CYP3A isoforms in the bioactivation of organophosphorothionate insecticides
    Franca M. Buratti, Claudia Leoni, Emanuela Testai · 2006 · Toxicology Letters
  75. Can Silicon Make an Excellent Drug Even Better? An in vitro and in vivo Head‐to‐Head Comparison between Loperamide and Its Silicon Analogue Sila‐Loperamide
    Marcel Geyer, Eric Wellner, Ulrik Jurva, Sebastian Saloman, Duncan Armstrong, Reinhold Tacke · 2015 · ChemMedChem
  76. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens
    Daniel Moj, Nina Hanke, Hannah Britz, Sebastian Frechen, Tobias Kanacher, Thomas Wendl, Walter E. Haefeli, Thorsten Lehr · 2016 · The AAPS Journal
  77. Catalytic turnover of pyrene by CYP3A4: Evidence that cytochrome b5 directly induces positive cooperativity
    Monica I. Jushchyshyn, James Matthew Hutzler, Michael L. Schrag, Larry C. Wienkers · 2005 · Archives of Biochemistry and Biophysics
  78. Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    Matthew G. Soars, Ken Grime, Robert J. Riley · 2006 · Xenobiotica
  79. A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?
    J. Andrew Williams, Jack Cook, Susan I. Hurst · 2003 · Drug Metabolism and Disposition
  80. Variation in Expression of Cytochrome P450 3A Isoforms and Toxicological Effects: Endo- and Exogenous Substances as Regulatory Factors and Substrates
    Chieri Fujino, Seigo Sanoh, Toshiya Katsura · 2021 · Biological and Pharmaceutical Bulletin
  81. Impact of CYP3A5 Genotype on Tacrolimus Versus Midazolam Clearance in Renal Transplant Recipients: New Insights in CYP3A5-Mediated Drug Metabolism
    Hylke de Jonge, Henriëtte de Loor, Kristin Verbeke, Yves F. Ch. Vanrenterghem, Dirk R. J. Kuypers · 2013 · Pharmacogenomics
  82. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach
    Kwang-Hee Shin, Li Young Ahn, Man Ho Choi, Ju-Yeon Moon, Jieon Lee, In‐Jin Jang, Kyung‐Sang Yu, Joo‐Youn Cho · 2016 · The AAPS Journal
  83. Fluorescent probes for the detection and imaging of Cytochrome P450
    Lei Feng, Jing Ning, Xiangge Tian, Chao Wang, Zhenlong Yu, Xiaokui Huo, Tian Xie, Baojing Zhang, Tony D. James, Xiaochi Ma · 2021 · Coordination Chemistry Reviews
  84. A Pharmacogenomics Primer
    Michael H. Court · 2007 · The Journal of Clinical Pharmacology
  85. Pharmacogenetic Determinants of Human Liver Microsomal Alfentanil Metabolism and the Role of Cytochrome P450 3A5
    Theresa Mariero Klees, Pamela R. Sheffels, Kenneth E. Thummel, Evan D. Kharasch · 2005 · Anesthesiology
  86. CYP3A Specifically Catalyzes 1β-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity
    Martin A. Hayes, Xueqing Li, Gunnar Grönberg, Ulf Diczfalusy, Tommy B. Andersson · 2016 · Drug Metabolism and Disposition
  87. Physiologically‐Based Pharmacokinetic Modeling Characterizes the CYP3A‐Mediated Drug‐Drug Interaction Between Fluconazole and Sildenafil in Infants
    Sara N. Salerno, Andrea N. Edginton, Jacqueline G. Gerhart, Matthew Maxwell Laughon, Namasivayam Ambalavanan, Gregory M. Sokol, Chi Dang Hornik, Dan L. Stewart, Mary Mills, Karen L Martz et al. · 2020 · Clinical Pharmacology & Therapeutics
  88. Challenges for drug studies in children: CYP3A phenotyping as example
    Saskia N. de Wildt, Shinya Ito, Gideon Koren · 2008 · Drug Discovery Today
  89. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
    Annika Allqvist, Jun Miura, Leif Bertilsson, Rajaa A. Mirghani · 2007 · European Journal of Clinical Pharmacology
  90. The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting
    Charles J. O’Donnell, Ken Grime, Paul F. Courtney, Dean Slee, Robert J. Riley · 2006 · Drug Metabolism and Disposition
  91. DIFFERENTIAL ENANTIOSELECTIVITY AND PRODUCT-DEPENDENT ACTIVATION AND INHIBITION IN METABOLISM OF VERAPAMIL BY HUMAN CYP3AS
    Lixin Shen, John F. Fitzloff, Chyung S. Cook · 2004 · Drug Metabolism and Disposition
  92. Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A
    Ping Zhao, Caroline A. Lee, Kent L. Kunze · 2007 · Drug Metabolism and Disposition
  93. Effect of CYP3A5 Expression on the Inhibition of CYP3A-Catalyzed Drug Metabolism: Impact on Modeling CYP3A-Mediated Drug-Drug Interactions
    Yoshiyuki Shirasaka, Shu Ying Chang, Mary F. Grubb, Chi-Chi Peng, Kenneth E. Thummel, Nina Isoherranen, A. David Rodrigues · 2013 · Drug Metabolism and Disposition
  94. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations
    Zoe E. Barter, H. F. Perrett, Karen Rowland Yeo, Delphine Allorge, Martin S Lennard, Amin Rostami‐Hodjegan · 2010 · Biopharmaceutics & Drug Disposition
  95. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients
    H. Kagaya, Masatomo Miura, Shigeru Satoh, Ken‐ichiro Inoue, Mitsuru Saito, Takamitsu Inoue, Tomonori Habuchi, T. Suzuki · 2008 · Journal of Clinical Pharmacy and Therapeutics
  96. Dynamics and Location of the Allosteric Midazolam Site in Cytochrome P4503A4 in Lipid Nanodiscs
    Michelle Redhair, John C. Hackett, Robert D. Pelletier, William M. Atkins · 2020 · Biochemistry
  97. Genetic polymorphisms associated with antiepileptic metabolism
    Sandra Adela Orozco-Suárez · 2014 · Frontiers in Bioscience-Elite
  98. To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics
    Sieto Bosgra, Maria L.H. Vlaming, Wouter H. J. Vaes · 2015 · Clinical Pharmacokinetics
  99. Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression
    Raju Khatri, Natasha Kulick, Rebecca J.B. Rementer, John K. Fallon, Craig Sykes, Amanda P. Schauer, Melina M. Malinen, Merrie Mosedale, Paul Brent Watkins, Angela D. M. Kashuba et al. · 2020 · Journal of Pharmaceutical Sciences
  100. Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3
    Teresa W. Tam, Rui Liu, John Thor Arnason, Anthony Krantis, William A. Staines, Pierre Selim Haddad, Brian C. Foster · 2009 · Journal of Ethnopharmacology